⚡ Quick Answer — What is Rami Race?
Rami Race is a 10 mg ramipril tablet from Torrent Pharmaceuticals — an angiotensin-converting enzyme (ACE) inhibitor. ACE inhibitors are first-line antihypertensive therapy in most international guidelines (NICE, AHA/ACC, ESC/ESH), particularly for patients under 55 and for diabetics, heart-failure patients, post-MI patients, and those with proteinuric kidney disease. Ramipril is a prodrug converted by hepatic esterases to ramiprilat (the active ACE inhibitor) with effective half-life 13-17 hours (ramiprilat) — supports once-daily dosing. Typical hypertension dose: start 1.25-2.5 mg once daily, titrate to 2.5-10 mg once daily. Main side effect: dry persistent cough (up to 20% of users, class effect; if intolerable, switch to an ARB such as losartan or telmisartan). Other class effects: hyperkalaemia, first-dose hypotension, reversible rise in creatinine at start. Absolutely contraindicated in pregnancy (all trimesters — causes fetal renal agenesis, oligohydramnios, pulmonary hypoplasia, skull defects), bilateral renal artery stenosis, and history of ACE-inhibitor-induced angioedema.
📦 Every order is covered by our Reshipment Assurance Policy — if your parcel does not arrive within 20 business days, we reship it.
Why order from MedsBase
Our generic medications are sourced from WHO-GMP certified manufacturers and shipped worldwide in discreet, plain packaging — no medication name on the parcel exterior. Card payments are routed through a regulated processor (statement descriptors include a regulated card-payment processor — never “MedsBase” or any medication name). Crypto and SEPA bank transfer are also accepted. Every order is backed by our Reshipment Assurance Policy.
What Is Rami Race?
Rami Race is an oral 10 mg ramipril tablet from Torrent Pharmaceuticals, supplied in 30-180 tablets. Introduced 1989 (Hoechst / now Sanofi) as Altace / Tritace. Most widely-prescribed ACE inhibitor worldwide.
Ramipril is a prodrug converted by hepatic esterases to ramiprilat (the active ACE inhibitor), with effective half-life 13-17 hours (ramiprilat) — supports once-daily dosing.
How Ramipril Lowers Blood Pressure
ACE inhibitors block the angiotensin-converting enzyme, which catalyses the conversion of inactive angiotensin I to active angiotensin II. Angiotensin II is a potent vasoconstrictor and the primary stimulus for adrenal aldosterone release. Blocking its formation produces:
- Direct arterial vasodilation — reduced systemic vascular resistance = lower blood pressure
- Reduced aldosterone secretion — less renal sodium and water retention
- Reduced preload (venous + modest ventricular unloading) — particularly important in heart failure
- Bradykinin accumulation — ACE also degrades bradykinin; blocking ACE raises bradykinin levels, which potentiates vasodilation (and causes the dry-cough side effect in ~20% of users)
- Reduced sympathetic nervous system activation
- Endothelial function improvement and reduced ventricular remodelling — responsible for the vascular-protective effects seen in trials (HOPE, EUROPA) that extend beyond BP lowering alone
Approved and Evidence-Based Uses
- Hypertension — primary indication, first-line per NICE, ESC/ESH, and AHA/ACC guidelines for most adults under 55 and for all ages with diabetes, CKD, or heart failure
- Cardiovascular risk reduction in patients with established atherosclerosis, prior MI, stroke, PVD, or diabetes + one additional risk factor (HOPE evidence)
- Heart failure with reduced ejection fraction (HF-REF) — AIRE trial
- Post-MI left-ventricular dysfunction
- Diabetic nephropathy — slows progression of albuminuria and renal function decline
- Non-diabetic proteinuric CKD
Pivotal trial evidence: HOPE trial (2000) — ramipril 10 mg/day reduced cardiovascular death, MI, and stroke by 22% in patients with established vascular disease or diabetes plus one risk factor. AIRE trial — 27% mortality reduction in post-MI HF. These trials established ACE inhibitors as vascular-protective agents, not just BP drugs.
Rami Race Dosage
Hypertension:
- Starting dose: 1.25-2.5 mg once daily
- Target dose: 2.5-10 mg once daily
- Maximum: 10 mg once daily
- Titrate every 2-4 weeks based on BP response and tolerability
Heart failure with reduced ejection fraction (HF-REF): Start 1.25-2.5 mg twice daily; titrate to 5 mg twice daily (HF-REF target)
Post-myocardial infarction: 5 mg twice daily starting 2-9 days post-MI
First-dose precautions: first-dose hypotension is most likely in patients on high-dose diuretics, in dehydrated patients, in heart failure, and in elderly patients. Take the first dose at bedtime; monitor BP; hold diuretics for 24-48 hours before starting if possible.
Monitoring:
- Baseline: urea, electrolytes (especially potassium), creatinine, eGFR. Get a blood pressure baseline.
- After 1-2 weeks: repeat U&E. Expected effects: small rise in creatinine (up to 30% is acceptable and reflects intrarenal haemodynamic change, not nephrotoxicity); small rise in potassium.
- After dose increase: repeat U&E at 1-2 weeks.
- Ongoing: annual U&E once stable.
- Stop and investigate: creatinine rise >30%, eGFR fall >25%, potassium >5.5, new hypotension / dizziness.
Discontinuation: tapering is not strictly required for ACE inhibitors (unlike beta-blockers), but abrupt discontinuation causes BP rebound within days. If stopping, taper over 1-2 weeks and monitor BP.
Side Effects
Common (>5%):
- Dry persistent cough (up to 20% — class effect due to bradykinin accumulation). Usually starts within weeks of beginning therapy; does not go away with time. If troublesome, switch to an ARB (losartan, telmisartan, olmesartan, valsartan, irbesartan) — ARBs do not cause cough because they act downstream of bradykinin metabolism.
- Dizziness, postural hypotension (particularly at start of therapy)
- Mild hyperkalaemia (check potassium)
- Reversible rise in serum creatinine (up to ~30% is expected and acceptable)
- Headache, fatigue
- Altered taste sensation (dysgeusia)
Uncommon but important:
- Angioedema — potentially life-threatening swelling of lips, tongue, airway. Incidence ~0.1-0.5%; higher in patients of African descent. Can occur after years of uneventful use. Stop immediately, seek emergency care, and do not restart any ACE inhibitor — also contraindicated for ARBs in first 4 weeks in patients with ACEi angioedema history.
- Acute kidney injury in bilateral renal artery stenosis — ACE inhibition removes the angiotensin-II-dependent efferent arteriolar constriction that maintains GFR in severely compromised renal perfusion. Usually reveals itself as a >30% creatinine rise within days of starting.
- Severe hyperkalaemia — particularly with potassium supplements, potassium-sparing diuretics (spironolactone), NSAIDs, or in CKD
- Neutropenia and agranulocytosis — very rare, mostly a historical concern from captopril
- Hepatic dysfunction / cholestatic jaundice — very rare
Contraindications
- Pregnancy — ABSOLUTE contraindication at all trimesters. ACE inhibitors cause fetal renal agenesis, oligohydramnios, pulmonary hypoplasia, and skull hypoplasia. Stop immediately if pregnancy occurs. Women of childbearing potential should use reliable contraception or switch to a pregnancy-safe antihypertensive (labetalol, methyldopa, nifedipine, hydralazine) before conception.
- History of ACE-inhibitor-induced angioedema — absolute; even a single past episode makes ACE inhibitors contraindicated for life
- Bilateral renal artery stenosis or stenosis in a single functioning kidney — AKI risk
- Hereditary or idiopathic angioedema
- Severe aortic stenosis — relative; can precipitate hypotension
- Hyperkalaemia >5.5 mmol/L at baseline (correct first)
- Concurrent sacubitril / valsartan (Entresto) — do not combine; 36-hour washout required
- Concurrent aliskiren in diabetes or CKD (direct renin inhibitor)
- Hypersensitivity to ramipril
Breastfeeding: enalapril and captopril are considered compatible (small amounts in breast milk); data for ramipril is limited — avoid in the first weeks after delivery of a premature infant; generally acceptable thereafter.
Drug Interactions
- Potassium-sparing diuretics (spironolactone, eplerenone, amiloride, triamterene) — additive hyperkalaemia; monitor K+ closely. The combination is clinically used in HF-REF but requires careful monitoring.
- Potassium supplements and salt substitutes containing potassium — hyperkalaemia risk
- NSAIDs (ibuprofen, diclofenac, naproxen) — reduce the antihypertensive effect of ACE inhibitors AND increase AKI risk (“triple whammy” = ACEi + diuretic + NSAID). Avoid chronic combination.
- Lithium — ACE inhibitors reduce renal lithium clearance; monitor lithium levels closely
- Other antihypertensives — usually complementary; monitor BP
- Sacubitril/valsartan (Entresto) — do not combine; 36-hour washout required to avoid angioedema risk
- Allopurinol — rare reports of increased hypersensitivity; clinically minor
- Aliskiren — avoid combination in diabetes and CKD (ALTITUDE trial stopped early for harm)
ACE Inhibitor Class at a Glance
| ACE Inhibitor | Activation | Best for / key trial |
|---|---|---|
| Ramipril (Ramcor, Rami Race, Ramgee, Ramisave) | Prodrug (liver → ramiprilat) | Vascular protection (HOPE); post-MI (AIRE) |
| Enalapril (Enapril) | Prodrug (liver → enalaprilat) | Heart failure (CONSENSUS, SOLVD) |
| Lisinopril (Lispro, Hypernil) | Active drug (no liver needed) | Preferred in hepatic impairment; HF (ATLAS); post-MI (GISSI-3) |
| Perindopril (Coversyl) | Prodrug (liver → perindoprilat) | Longest half-life; HTN (ASCOT-BPLA); CAD (EUROPA); stroke prevention (PROGRESS) |
| Captopril | Active drug | Short half-life (6 h); historical reference agent; rarely first-line now |
ACE Inhibitor vs ARB — Which to Use?
Angiotensin receptor blockers (ARBs — losartan, telmisartan, olmesartan, valsartan, irbesartan) work on the same renin-angiotensin pathway but block angiotensin II at its AT1 receptor rather than blocking its formation. Clinical effect on BP is broadly equivalent. Differences:
- No dry cough with ARBs — they don’t raise bradykinin levels. ARBs are the first choice after ACEi cough.
- Angioedema is rare but possible with ARBs — do NOT start an ARB within 4 weeks of an ACEi-angioedema episode; longer-term ARB use in previous ACEi-angioedema patients is generally acceptable but monitored.
- Cost — generic ACE inhibitors are slightly cheaper than generic ARBs in most markets
- Heart failure evidence — ACE inhibitors have slightly stronger historical mortality evidence; ARBs are validated as equivalent in more recent trials and used when ACEi is not tolerated
- Do NOT combine ACEi + ARB — ONTARGET trial showed harm (more hyperkalaemia, AKI, hypotension) without additional mortality benefit
Storage
Store Rami Race below 25°C in the original blister pack. Protect from moisture. Keep out of reach of children.
Frequently Asked Questions
How long does Rami Race take to lower blood pressure?
Initial BP drop within 1-2 hours of the first dose; full antihypertensive effect at 2-4 weeks as the renin-angiotensin system fully adjusts. Measure home BP at the same time each day to track response.
Why did I develop a cough after starting Rami Race?
ACE inhibitors raise bradykinin levels in the respiratory tract, causing a characteristic dry, persistent cough in up to 20% of users. It usually starts within days to weeks, does not improve with antitussives, and does not resolve while continuing the drug. If the cough is bothersome, switch to an ARB (losartan, telmisartan, olmesartan) — the cough resolves within 1-4 weeks of stopping the ACE inhibitor.
Can I take Rami Race in pregnancy?
No — ACE inhibitors are absolutely contraindicated in pregnancy. They cause fetal renal agenesis, oligohydramnios, pulmonary hypoplasia, and skull hypoplasia. Stop immediately if pregnancy occurs and switch to a pregnancy-safe antihypertensive — labetalol, methyldopa, nifedipine, or hydralazine. Women of childbearing potential should use reliable contraception.
My creatinine went up after starting Rami Race — should I stop?
A creatinine rise of up to 30% within the first 1-2 weeks is expected and acceptable — it reflects intrarenal haemodynamic adjustment as the angiotensin-II-dependent efferent arteriolar constriction is removed, not nephrotoxicity. A rise of >30% suggests possible bilateral renal artery stenosis, volume depletion, or NSAID interaction — stop the drug and investigate.
Can I drink alcohol on Rami Race?
Moderate alcohol is generally acceptable but alcohol is additive with the vasodilator effect — you may feel dizzy on standing up after drinking. Heavy drinking also independently raises BP; reducing alcohol often improves BP control independent of Rami Race.
Should I avoid potassium-rich foods on Rami Race?
Moderate intake of potassium-rich foods (bananas, oranges, spinach, avocado) is fine for most patients. Avoid potassium supplements (slow-K tablets) and salt substitutes containing potassium chloride unless specifically prescribed — these can cause dangerous hyperkalaemia when combined with ACE inhibitors, particularly in CKD or with potassium-sparing diuretics.
Can I take ibuprofen while on Rami Race?
Occasional short-term NSAID use is usually acceptable, but chronic daily NSAIDs (ibuprofen, diclofenac, naproxen) reduce the antihypertensive effect of ACE inhibitors AND substantially raise the AKI risk — particularly when combined with a diuretic (“triple whammy” = ACEi + diuretic + NSAID). For chronic pain, paracetamol is safer; for inflammation, discuss alternatives with your doctor.
Can I take Rami Race with my other BP medications?
Yes — ACE inhibitors combine well with calcium-channel blockers (amlodipine, nifedipine), thiazide diuretics (HCTZ, indapamide), beta-blockers (bisoprolol, metoprolol), and aldosterone antagonists (spironolactone — monitor K+). Do not combine with an ARB (ONTARGET trial showed harm with no benefit).
What if I miss a dose?
Take it as soon as you remember, unless it is nearly time for the next dose — in that case skip the missed dose and continue your normal schedule. Do not double up. A single missed dose won’t meaningfully affect BP control because ACE inhibitors have long-lasting pharmacological effects via tissue binding.
Where can I buy Rami Race online?
You can buy Rami Race (ramipril 10 mg, 30-180 tablets) from MedsBase with discreet packaging and worldwide shipping.
Related Antihypertensives on MedsBase
- Amlode — Amlodipine CCB
- Aquazide — Hydrochlorothiazide
- Cosart — Losartan (ARB alternative)
- Enapril — Enalapril 2.5/5/10 mg
- Hypernil — Lisinopril 10 mg
- Lipril-H — Lisinopril + HCTZ combo
- Browse all High Blood Pressure Medications
Related Alternatives
Other products in Chronic Conditions that customers also view:



























Reviews
There are no reviews yet